Free Trial
NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Maravai LifeSciences logo
$2.76 +0.16 (+6.15%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.72 -0.03 (-1.27%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Key Stats

Today's Range
$2.59
$2.81
50-Day Range
$1.96
$2.77
52-Week Range
$1.67
$10.03
Volume
2.46 million shs
Average Volume
2.28 million shs
Market Capitalization
$702.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.64
Consensus Rating
Hold

Company Overview

Maravai LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

MRVI MarketRank™: 

Maravai LifeSciences scored higher than 75% of companies evaluated by MarketBeat, and ranked 223rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Maravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 7 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Maravai LifeSciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Maravai LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.24) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Maravai LifeSciences is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Maravai LifeSciences is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Maravai LifeSciences has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Maravai LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    12.55% of the float of Maravai LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Maravai LifeSciences has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Maravai LifeSciences has recently decreased by 4.54%, indicating that investor sentiment is improving.
  • Dividend Yield

    Maravai LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Maravai LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.55% of the float of Maravai LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Maravai LifeSciences has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Maravai LifeSciences has recently decreased by 4.54%, indicating that investor sentiment is improving.
  • News Sentiment

    Maravai LifeSciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Maravai LifeSciences this week, compared to 10 articles on an average week.
  • Search Interest

    1 people have searched for MRVI on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.11% of the stock of Maravai LifeSciences is held by insiders.

  • Percentage Held by Institutions

    50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Maravai LifeSciences' insider trading history.
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

MRVI Stock News Headlines

The Recession Already Started, Are You Prepared?
Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Americans are shifting savings out of traditional accounts to protect what they’ve earned. If you’re concerned about inflation, rising debt, or a falling dollar, this free Wealth Protection Kit includes three timely reports to help you prepare for what’s coming next.
See More Headlines

MRVI Stock Analysis - Frequently Asked Questions

Maravai LifeSciences' stock was trading at $5.45 at the beginning of the year. Since then, MRVI stock has decreased by 49.4% and is now trading at $2.76.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced its earnings results on Monday, May, 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. Maravai LifeSciences's revenue for the quarter was down 26.9% compared to the same quarter last year.
Read the conference call transcript
.

Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/12/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRVI
CIK
1823239
Fax
N/A
Employees
610
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$2.00
Potential Upside/Downside
+140.5%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$144.85 million
Pretax Margin
-120.56%

Debt

Sales & Book Value

Annual Sales
$259.18 million
Cash Flow
$0.66 per share
Price / Cash Flow
4.21
Book Value
$2.28 per share
Price / Book
1.21

Miscellaneous

Free Float
249,287,000
Market Cap
$702.86 million
Optionable
Optionable
Beta
0.28
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:MRVI) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners